osimertinib,lazertinib,amivantamab-vmjw
oscotec,yuhan corp,astrazeneca,genmab,janssen
['lcsm,(-blcsm)', 'lazertinib', 'sclc', 'nsclc', 'chrysalis-2']
#asco22 chrysalis-2 trial amivantamab+lazertinib in egfr-mt nsclc post osi &amp; chemo: - 162 pts - orr=33% (another great )
- mpfs=5.1m; mos=14.8m potentially practice-changing now? ongoing analysis of mech of resistance, exploration in 1l #lcsm 
Thoracic Oncologist focused on immunotherapy for lung cancer & immune toxicity. Beaumont RCSI Cancer Centre Dublin; Adjunct Asst Prof Johns Hopkins University